Benefits and Risks of Newborn Screening for Cystic Fibrosis

Summary

Although cystic fibrosis (CF) is the most common, life-threatening autosomal recessive genetic disorder of the white population, there are often delays in diagnosis and hence start of treatment. Advances of the past two decades have made CF screening feasible using routinely collected neonatal blood specimens and measuring an enzyme level followed by CF mutation DNA analysis. Our overall goal of the study is to see if early diagnosis of CF through neonatal screening will be medically beneficial without major risks. ''Medically beneficial'' refers to better nutrition and/or pulmonary status, whereas '' risks'' include laboratory errors, miscommunication or misunderstanding, and adverse psychosocial consequences. Specific aims include assessment of the benefits, risks, costs, quality of life, and cognitive function associated with CF neonatal screening and a better understanding of the epidemiology of CF.

A comprehensive, randomized clinical trial emphasizing early diagnosis as the key variable has been underway since 1985. Nutritional status has been assessed using height and weight measurements and biochemical methods. The results have demonstrated significant benefits in the screened (early diagnosis) group. We are now focusing on the effect of early diagnosis of CF on pulmonary outcome. Pulmonary status is measured using chest radiographs, chest scans using high resolution computerized tomography, and pulmonary function tests. Other factors that we are looking at include risk factors for the acquisition of respiratory pathogens such as Pseudomonas aeruginosa, quality of life and cognitive function of children with CF who underwent early versus delayed diagnosis, as well as the cost effectiveness of screening and the costs of diagnosis and treatment of CF throughout childhood.

If the questions underlying this study are answered favorably, it is likely that neonatal screening using a combination of enzyme level (immunoreactive trypsinogen) and DNA test will become the routine method for identifying new cases of CF not only in the State of Wisconsin, but throughout the country.

Conditions

• Cystic Fibrosis
• Lung Disease
• Pseudomonas Infections

Interventions

PROCEDURE

CF newborn screening

Sponsors & Collaborators

• National Center for Research Resources (NCRR)

  collaborator NIH

• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

  lead NIH

Principal Investigators

• Philip M. Farrell, MD, PhD · Dean University of Wisconsin Medical School

• Michael J. Rock, M.D. · Dept. Pediatrics, UW Hospital

• Mark Splaingard · Children's Hospital and Health System Foundation, Wisconsin

• Anita Laxova · Dept. Pediatrics, UW Madison

Study Design

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Model

SINGLE_GROUP

Eligibility

Min Age

1 Month

Max Age

21 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Countries

• United States

Study Locations